Skip to main content
Premium Trial:

Request an Annual Quote

Guardant Health, AstraZeneca Partner on Liquid Biopsy CDx for Breast Cancer Drug

NEW YORK — Guardant Health said on Thursday that it has signed an agreement to develop its Guardant360 CDx blood-based liquid biopsy assay as a companion diagnostic for a breast cancer drug being developed by AstraZeneca.

Under the terms of the deal, the companies will work together to develop and commercialize the test as a way to identify patients with ESR1-mutated metastatic breast cancer who would be eligible for enrollment in a Phase III trial of AstraZeneca's camizestrant, a next-generation oral selective estrogen receptor degrader. The study is comparing the drug combination with aromatase inhibitors in combination with CDK4/6 inhibitors in patients with HR-positive, HER2-negative metastatic breast cancer.

Additional terms were not disclosed.

"We look forward to exploring the potential benefit of early comprehensive genomic profiling using a simple blood draw, which can provide faster results than a tissue biopsy and enable clinicians to consider earlier intervention with the goal of achieving improved patient outcomes," Guardant Chairman and co-CEO Helmy Eltoukhy said in a statement.

The alliance is part of a broader strategic collaboration between Palo Alto, California-based Guardant and AstraZeneca. In late 2018, the companies forged a multi-year partnership to develop blood-based companion diagnostic tests for drugs in the UK-based pharmaceutical firm's oncology portfolio.

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.